[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Artivion Inc (AORT)

Artivion Inc (AORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,180,080
  • Shares Outstanding, K 48,543
  • Annual Sales, $ 441,330 K
  • Annual Income, $ 9,770 K
  • EBIT $ 37 M
  • EBITDA $ 60 M
  • 60-Month Beta 1.26
  • Price/Sales 2.54
  • Price/Cash Flow 20.99
  • Price/Book 2.49

Options Overview Details

View History
  • Implied Volatility 74.57% (-6.84%)
  • Historical Volatility 49.41%
  • IV Percentile 70%
  • IV Rank 13.16%
  • IV High 343.80% on 11/28/25
  • IV Low 33.76% on 08/12/25
  • Expected Move (DTE 35) 2.98 (11.56%)
  • Put/Call Vol Ratio 0.46
  • Today's Volume 35
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 401
  • Open Int (30-Day) 370
  • Expected Range 22.76 to 28.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.13
  • Number of Estimates 1
  • High Estimate $0.13
  • Low Estimate $0.13
  • Prior Year $0.24
  • Growth Rate Est. (year over year) -45.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.08 +28.11%
on 06/23/26
26.06 -1.27%
on 07/16/26
+4.28 (+19.95%)
since 06/16/26
3-Month
19.16 +34.29%
on 05/08/26
39.66 -35.12%
on 04/21/26
-11.01 (-29.97%)
since 04/16/26
52-Week
19.16 +34.29%
on 05/08/26
48.25 -46.67%
on 12/17/25
-5.76 (-18.29%)
since 07/16/25

Most Recent Stories

More News
3 Reasons to Sell AORT and 1 Stock to Buy Instead

3 Reasons to Sell AORT and 1 Stock to Buy Instead

AORT : 25.73 (+5.84%)
3 Stocks Under $50 with Warning Signs

3 Stocks Under $50 with Warning Signs

IP : 37.87 (+3.08%)
SGRY : 16.64 (+4.72%)
AORT : 25.73 (+5.84%)
2 Growth Stocks Set to Flourishand 1 We Ignore

2 Growth Stocks Set to Flourishand 1 We Ignore

WK : 56.97 (+4.76%)
NXT : 106.85 (-2.09%)
AORT : 25.73 (+5.84%)
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

ATLANTA , June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration...

AORT : 25.73 (+5.84%)
3 Profitable Stocks We Keep Off Our Radar

3 Profitable Stocks We Keep Off Our Radar

TSLA : 391.06 (-0.86%)
MTD : 1,335.09 (+1.41%)
AORT : 25.73 (+5.84%)
1 of Wall Street’s Favorite Stocks with Solid Fundamentals and 2 We Question

1 of Wall Street’s Favorite Stocks with Solid Fundamentals and 2 We Question

NDAQ : 94.25 (+3.16%)
GPC : 125.66 (+3.85%)
AORT : 25.73 (+5.84%)
Artivion to Participate in the 2026 Truist Securities MedTech Conference

ATLANTA , June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the...

AORT : 25.73 (+5.84%)
Q1 Earnings Outperformers: Artivion (NYSE:AORT) And The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks

Q1 Earnings Outperformers: Artivion (NYSE:AORT) And The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks

AORT : 25.73 (+5.84%)
3 High-Flying Stocks Walking a Fine Line

3 High-Flying Stocks Walking a Fine Line

LASR : 65.69 (-3.14%)
AZTA : 26.78 (+0.26%)
AORT : 25.73 (+5.84%)
3 Healthcare Stocks We Keep Off Our Radar

3 Healthcare Stocks We Keep Off Our Radar

EHC : 112.49 (+2.38%)
ELAN : 25.95 (+1.61%)
AORT : 25.73 (+5.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Artivion Inc. is a medical device company. It focused on developing simple, elegant solutions which address cardiac and vascular surgeons. The company's group of products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts and surgical sealants....

See More

Key Turning Points

3rd Resistance Point 28.13
2nd Resistance Point 27.10
1st Resistance Point 26.41
Last Price 25.73
1st Support Level 24.69
2nd Support Level 23.66
3rd Support Level 22.97

See More

52-Week High 48.25
Fibonacci 61.8% 37.14
Fibonacci 50% 33.71
Fibonacci 38.2% 30.27
Last Price 25.73
52-Week Low 19.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.